Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trials
Japanese trial data show efficacy of monoclonal antibody on rheumatoid arthritis patients
May 18th, 2006
Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, and F. Hoffmann-La Roche Ltd., Basel, Switzerland, announced that the humanized antihuman IL-6 (interleukin-6) receptor monoclonal antibody Actemra (tocilizumab injection), co-developed by Chugai and Roche, has shown efficacy as a monotherapy in rheumatoid arthritis patients in a double-blind phase 3 trial conducted in Japan. The results were presented at The Japan College of Rheumatology (JCR) Annual Scientific Meeting held in Nagasaki, Japan. The trial objective was to determine Actemra's clinical efficacy and safety for rheumatoid arthritis patients with inadequate response to methotrexate (MTX)...
Source: Biotech Business Week (2006-05-18)
|
